You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Zepbound ® (tirzepatide) injection
2.5 mg/ 5 mg/ 7.5 mg/ 10 mg/ 12.5 mg/ 15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Can Zepbound® (tirzepatide) be used in people with blood disorders such as sickle cell disease or hemolytic anemia?
Tirzepatide has not been studied in people with sickle cell disease or hemolytic anemia.
See important safety information, including boxed warning, in the attached prescribing information.
Blood Disorders
No information is available on the use of tirzepatide with comorbid sickle cell disease or hemolytic anemia because participants were excluded from clinical studies if they had any blood condition that may interfere with glycated hemoglobin (HbA1c) measurement.
Enclosed Prescribing Information
References
Date of Last Review: December 18, 2024